Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
Scientific News
Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial
Liberia-U.S. partnership planning Phase 3 trial and study of Ebola survivors.
NIH Works to Improve Kidney Health for All
Statement of NIDDK Director Griffin P. Rodgers, M.D., for World Kidney Day 2015.
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study
Phase 1 study to evaluate the novel oncology immunotherapeutic MOR209/ES414 for prostate cancer.
NIH-supported Clinical Trials to Evaluate Long-acting, Injectable Antiretroviral Drugs
Both trials are expected to be completed in 2017.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Paramedics May be First Line of Treatment for Stroke
NIH study demonstrates feasibility of getting drugs to stroke patients faster.
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
Ebola Vaccine Trial Opens in Liberia
Study led by Liberia-NIH partnership will test two experimental vaccines.
NIH Launches Tool to Advance Down Syndrome Research
Web portal will help approved professionals to plan clinical studies.
NIH Researchers Tackle Thorny Side of Gene Therapy
Pre-clinical studies in mice reveal ways to reduce cancer risk with modified treatment.
Scroll Up
Scroll Down
Return
Challenges of Implementing and Validating CTC Assays in Oncology Clinical Trials
Iman Jilani, Pfizer, speaking at Exosomes and Circulating Biomarkers Summit 2013.
Date Posted: Sunday, March 30, 2014
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Related Content

Pfizer to Acquire Hospira for $17B
Companies have into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.
Thursday, February 05, 2015
Pfizer Acquires Redvax
Acquisition provides Pfizer with a preclinical CMV vaccine candidate.
Thursday, January 08, 2015
Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform
Signs collaboration with Spark Therapeutics to advance phase 1/2 Adeno-associated virus (AAV) vector program in hemophilia B.
Friday, December 12, 2014
Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer Presents Phase 3 Safety And Immunogenicity Data On HIV Drug
Pfizer Inc. presented the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13® in adults infected with HIV.
Tuesday, March 05, 2013
Pfizer Announces Positive Results From Phase 3 Cancer Study
Study PROFILE 1007 evaluates XALKORI® (crizotinib) in previously treated patients with ALK-positive advanced non-small cell lung cancer.
Wednesday, June 27, 2012
Pfizer Receives FDA Approval for Geodon® Capsules for the Adjunctive Maintenance Treatment of Bipolar Disorder in Adults
Data show Geodon used as an adjunct to Lithium or Valproate Is effective in the maintenance treatment of Bipolar I disorder.
Monday, November 23, 2009
Pfizer and Private Access Announce Plans to Develop Online Community to Accelerate Clinical Research
Privacy-enhanced search technology addresses privacy concerns to increase patient participation.
Monday, August 31, 2009
 
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters